What is OPTIZORB® technology and how does it work?
Paracetamol tablets are, readily available, effective and suitable for large numbers of people. However, standard paracetamol tablets are sometimes slow to dissolve and absorb, and can sometimes take a long time to have an effect. The makers of PANADOL have developed a patented technology which allows the tablet to start disintegrating in as little as 5 minutes - this new technology is called Optizorb.
What happens when you swallow a tablet?
Stage 1 Disintegration - the tablet breaks apart into smaller pieces called granules
Stage 2 Dissolution - The granules break into particles small enough to dissolve in the stomach
Stage 3 Absorption - The particles are finally absorbed throughout the body and into the bloodstream – where the medicine can take effect
What makes tablets containing Optizorb® technology different?
Unlike standard paracetamol tablets, Panadol Advance contains Optizorb® technology. This allows the tablet to be absorbed rapidly so that it can get to work.
Optizorb® technology is a combination of ingredients, which work together to speed up the rate at which the paracetamol tablet disintegrates and dissolves in the stomach.
- A naturally occurring substance that makes the tablet act like a sponge so when it reaches the stomach it soaks up water, swells then breaks apart.
- A common ingredient widely used in tablet formulations that, on contact with the stomach acids, releases small amounts of carbon dioxide which helps the tablet break up.
- A ‘super-disintegrant’ which causes the tablet to swell even more, and speeds up the break up process.
As a result the tablet breaks apart quickly and so can start to work faster. In a clinical study PANADOL Advance tablets that contain Optizorb technology were shown to start relieving pain in just 15 minutes1.
- Wilson CG, Clarke CP, Starkey YY, Clarke GD. Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. Drug Dev Ind Pharm. 2011;37(7):747-753.